Skip to main navigation Skip to search Skip to main content

Time to Reperfusion and Treatment Effect for Acute Ischemic Stroke A Randomized Clinical Trial

  • Puck Fransen
  • , Olvert Berkhemer
  • , Hester Lingsma
  • , D Beumer
  • , LA van den Berg
  • , AJ Yoo
  • , WJ Schonewille
  • , JA Vos
  • , PJ Nederkoorn
  • , MJH Wermer
  • , MAA Walderveen
  • , J Staals
  • , J Hofmeijer
  • , JA van Oostayen
  • , GJLA Nijeholt
  • , J Boiten
  • , Patrick Brouwer
  • , Bart Emmer
  • , SF de Bruijn
  • , Lucas Dijk
  • LJ Kappelle, RH Lo, EJ van Dijk, J Vries, PLM de Kort, JSP van den Berg, BAAM van Hasselt, LAM Aerden, RJ Dallinga, MC Visser, JCJ Bot, PC Vroomen, O Eshghi, THCML Schreuder, RJJ Heijboer, K Keizer, AV Tielbeek, HM den Hertog, DG Gerrits, RM van den Berg-Vos, GB Karas, Ewout Steyerberg, HZ (Zwenneke) Flach, HA Marquering, MES Sprengers, Sjoerd Jenniskens, LFM Beenen, Robert Berg, Peter Koudstaal, WH Zwam, YBWEM Roos, RJ van Oostenbrugge, CBLM Majoie, Aad van der Lugt, Diederik Dippel
  • External organisation

Research output: Contribution to journalArticleAcademicpeer-review

239 Citations (Scopus)

Abstract

IMPORTANCE Intra-arterial treatment (IAT) for acute ischemic stroke caused by intracranial arterial occlusion leads to improved functional outcome in patients treated within 6 hours after onset. The influence of treatment delay on treatment effect is not yet known. OBJECTIVE To evaluate the influence of time from stroke onset to the start of treatment and from stroke onset to reperfusion on the effect of IAT. DESIGN, SETTING, AND PARTICIPANTS The Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) was a multicenter, randomized clinical open-label trial of IAT vs no IAT in 500 patients. The time to the start of treatment was defined as the time from onset of symptoms to groin puncture (TOG). The time from onset of treatment to reperfusion (TOR) was defined as the time to reopening the vessel occlusion or the end of the procedure in cases for which reperfusion was not achieved. Data were collected from December 3, 2010, to June 3, 2014, and analyzed (intention to treat) from July 1, 2014, to September 19, 2015. MAIN OUTCOMES AND MEASURES Main outcome was the modified Rankin Scale (mRS) score for functional outcome (range, 0 [no symptoms] to 6 [death]). Multiple ordinal logistic regression analysis estimated the effect of treatment and tested for the interaction of time to randomization, TOG, and TOR with treatment. The effect of treatment as a risk difference on reaching independence (mRS score, 0-2) was computed as a function of TOG and TOR. Calculations were adjusted for age, National Institutes of Health Stroke Scale score, previous stroke, atrial fibrillation, diabetes mellitus, and intracranial arterial terminus occlusion. RESULTS Among 500 patients (58% male; median age, 67 years), the median TOG was 260 (interquartile range [IQR], 210-311) minutes; median TOR, 340 (IQR, 274-395) minutes. An interaction between TOR and treatment (P = .04) existed, but not between TOG and treatment (P = .26). The adjusted risk difference (95% CI) was 25.9% (8.3%-44.4%) when reperfusion was reached at 3 hours, 18.8% (6.6%-32.6%) at 4 hours, and 6.7% (0.4%-14.5%) at 6 hours. CONCLUSION AND RELEVANCE For every hour of reperfusion delay, the initially large benefit of IAT decreases; the absolute risk difference for a good outcome is reduced by 6% per hour of delay. Patients with acute ischemic stroke require immediate diagnostic workup and IAT in case of intracranial arterial vessel occlusion.
Original languageUndefined/Unknown
Pages (from-to)190-196
Number of pages7
JournalJAMA Neurology
Volume73
Issue number2
DOIs
Publication statusPublished - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research programs

  • EMC COEUR-09
  • EMC NIHES-02-65-01
  • EMC NIHES-03-30-01

Cite this